AKT1 and central nervous system cancer: miR-26a delivered from glioma stem cells into microvessel endothelial cells (MVECs) via EVs could potentially provide an effective therapeutic strategy for glioma by controlling phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and regulating the phosphatidylinositol 3-kinase/protein kinase B (PI3K-Akt) pathway [20].